AEON Biopharma annual stock-based compensation
2021
2022
2023
2024
2025
AEON Biopharma Stock-Based Compensation Growth & History (AEON)
AEON Biopharma's stock-based compensation was $5.3M for fiscal 2025.
View full AEON Biopharma company overviewAEON Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.3M | −$933,000 | −14.93% |
| 2024 | 2024-12-31 | $6.3M | $2.5M | +65.96% |
| 2023 | 2023-12-31 | $3.8M | −$2.1M | −36.08% |
| 2022 | 2022-12-31 | $5.9M | $672,000 | +12.87% |
| 2021 | 2021-12-31 | $5.2M | — | — |
AEON Biopharma quarterly stock-based compensation
Q1.23
Q2.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | $77,000 | +4.87% |
| Q1 2026 | 2026-03-31 | $1.9M | $203,000 | +11.74% |
| Q4 2025 | 2025-12-31 | $1.6M | $250,000 | +18.63% |
| Q3 2025 | 2025-09-30 | $414,000 | −$1.2M | −74.03% |
| Q2 2025 | 2025-06-30 | $1.6M | −$111,000 | −6.56% |
| Q1 2025 | 2025-03-31 | $1.7M | $108,000 | +6.66% |
| Q4 2024 | 2024-12-31 | $1.3M | — | — |
| Q3 2024 | 2024-09-30 | $1.6M | −$577,000 | −26.58% |
| Q2 2024 | 2024-06-30 | $1.7M | — | — |
| Q1 2024 | 2024-03-31 | $1.6M | $261,000 | +19.19% |
| Q3 2023 | 2023-09-30 | $2.2M | — | — |
| Q2 2023 · Jul 21 | 2023-07-21 | $730,000 | — | — |
| Q2 2023 · Jun 30 | 2023-06-30 | $1.1M | — | — |
| Q1 2023 | 2023-03-31 | $1.4M | — | — |
AEON Biopharma stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, AEON Biopharma's stock-based compensation increased from $5.2M to $5.3M, a change of $97,000. The latest reported quarter, Q2 2026, shows $1.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AEON Biopharma source filings ↗